GlassScriptPhysician profile
Skeena Deen
NPI 1386290039
$5,379.61
in general payments reported to CMS, 2019-2025
30 companies · $709 in 2025
The $709 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,126 · 2022: $1,049 · 2023: $199 · 2024: $297 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,581.70 | 2021-2024 | Proclaim |
| Nalu Medical, INC. | $1,126.28 | 2021-2025 | Nalu Neurostimulation System |
| Nevro Corp. | $633.38 | 2021-2024 | Senza |
| Boston Scientific Corporation | $373.11 | 2021-2022 | |
| Curonix LLC | $136.94 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Almatica Pharma LLC | $129.12 | 2021 | |
| Abbvie INC. | $126.41 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $126.11 | 2021-2022 | |
| Relievant Medsystems, INC. | $112.66 | 2021 | |
| Globus Medical, INC. | $105.76 | 2025 | Senza |
| Horizon Therapeutics Plc | $96.08 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $94.69 | 2021 | |
| Biotronik Nro, INC. | $88.55 | 2025 | Prospera |
| Spr Therapeutics, INC | $87.01 | 2021 | |
| Medtronic, INC. | $80.78 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $61.57 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.35 | 2022-2025 | Relistor |
| Amgen INC. | $49.64 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $48.56 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $48.17 | 2025 | |
| Si-Bone, INC. | $45.97 | 2025 | |
| Hikma Pharmaceuticals USA | $34.88 | 2021-2022 | |
| Saluda Medical Americas, INC. | $25.47 | 2025 | Evoke |
| Zoll Respicardia, INC. | $19.67 | 2023 | Remede System |
| Biohaven Pharmaceutical Holding Company LTD. | $18.36 | 2022 | |
| Otto Bock Healthcare LP | $17.38 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.26 | 2021 | |
| Alfasigma USA, INC. | $15.29 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.59 | 2024 | Horizant |
| Electronic Waveform Lab, INC. | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skeena Deen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.